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in Dublin
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Abstract
Background: Guidelines for safe gamete donation have emphasised donor screening, although none exist
specifically for testing oocyte recipients. Pre-treatment assessment of anonymous donor oocyte IVF treatment in
Ireland must comply with the European Union Tissues and Cells Directive (Directive 2004/23/EC). To determine the
effectiveness of this Directive when applied to anonymous oocyte recipients in IVF, we reviewed data derived from
selected screening tests performed in this clinical setting.
Methods: Data from tests conducted at baseline for all women enrolling as recipients (n = 225) in the anonymous
oocyte donor IVF programme at an urban IVF referral centre during a 24-month period were analysed. Patient age
at programme entry and clinical pregnancy rate were also tabulated. All recipients had at least one prior negative
test for HIV, Hepatitis B/C, chlamydia, gonorrhoea and syphilis performed by her GP or other primary care provider
before reproductive endocrinology consultation.
Results: Mean (±SD) age for donor egg IVF recipients was 40.7 ± 4.2 yrs. No baseline positive chlamydia,
gonorrhoea or syphilis screening results were identified among recipients for anonymous oocyte donation IVF
during the assessment interval. Mean pregnancy rate (per embryo transfer) in this group was 50.5%.
Conclusion: When tests for HIV, Hepatitis B/C, chlamydia, gonorrhoea and syphilis already have been confirmed to
be negative before starting the anonymous donor oocyte IVF sequence, additional (repeat) testing on the recipient
contributes no new clinical information that would influence treatment in this setting. Patient safety does not
appear to be enhanced by application of Directive 2004/23/EC to recipients of anonymous donor oocyte IVF
treatment. Given the absence of evidence to quantify risk, this practice is difficult to justify when applied to this
low-risk population.
Introduction
Since 2006, the European Union Tissues and Cells
Directive (Directive 2004/23/EC) has exerted an impor-
tant regulatory impact on the provision of clinical ferti-
lity practice in the E.U [1]. This legislation was designed
to ensure the safety of donated tissue including bone
marrow, corneas, stem cells and heart valves provided
through organ/tissue donation. However, IVF clinics in
Europe found that they too were under the remit of this
directive, since, from a technical and legislative
standpoint, couples were regarded as “donating” their
own eggs and sperm to each other during fertility proce-
dures. E.U. member states have applied this testing
requirement to their constituent IVF clinics in different
ways. This process continues to evolve in the Republic
of Ireland, and accumulated evidence is beginning to
show that there is room for improvement in how IVF
patients are screened before treatment [2].
Studies of screening test results have found the cur-
rent testing approach has a very poor yield when applied
to non-donor IVF cycles in Ireland [3]. Indeed, anon-
ymous oocyte donors matched to recipients in Ireland
were confirmed to be low-risk as well [1]. But until
now, there has not been any detailed analysis of basic
screening data from recipients of anonymous donor
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oocyte IVF cycles in Ireland. The current investigation
describes these Irish recipients of anonymous donor
oocyte IVF treatment with specific attention to their
HIV, Hepatitis B/C, chlamydia, gonorrhoea, and syphilis
test results.
Methods
Study population and specimen collection
Written informed consent was obtained from all
patients (n = 225) who enrolled in the anonymous
donor oocyte IVF sequence at The Sims Institute
(Dublin)/Sims IVF during a 24-month period ending
January 2011. Because the study site is the only provider
of anonymous donor oocyte IVF service in the Republic
of Ireland, the geographical catchment area includes the
entire state (patients from other jurisdictions also
obtained treatment here, but data from foreign indivi-
duals were not stratified for separate analysis). All
donor-egg IVF cycles reviewed in this study incorpo-
rated sperm provided by a known partner who was also
separately evaluated, rather than from an anonymous
sperm donor [4]. All participants underwent formal psy-
chological counselling in advance of anonymous donor
oocyte IVF and each patient received standard clinical
examination. Tests for Chlamydia and syphilis were
done either by serological (blood test) method, cervical
swab, or urine test in compliance with Directive 2004/
23/EC. In contrast, this directive does not require sepa-
rate testing for N. gonorrhoea although this test was per-
formed based on current ASRM testing guidelines for
oocyte recipients in the United States [5]. All specimens
were processed at a registered INAB licensed laboratory
accredited to ISO medical testing standards. Blood sam-
ples were collected in appropriate vacutainer tubes in a
non-fasting, random state via peripheral venipuncture
(sample volume 5-10 ml). Urine samples were collected
at least 2 h after previous urination (sample volume =
10-20 ml). Cervical swabs were collected at pre-enrol-
ment assessment during speculum exam at this centre.
All specimens were sent to our diagnostic laboratory,
transported neat for examination within 48 h.
Overview of specific testing platforms
Chlamydia
Testing was via PCR test performed either on cervical
swab or random urine sample (these testing modalities
have been determined to be of equivalent accuracy and
sensitivity) [6]. The test amplifies a fragment of species
specific DNA from the plasmid of the Chlamydia organ-
ism which is present in the female reproductive tract,
and has sufficient sensitivity to detect a single chlamydia
cell in the sample submitted for analysis. The PCR test
for C. trachomatis had no cross-reactivity with antigens
from C. pneumoniae or C. psittaci (psittacosis), which
require different detection methods.
Gonorrhoea
Urine samples were used to detect bacterial N. gonor-
rhoeae DNA via spin-column chromatography and PCR
amplification. The amplified PCR products were then
further studied by agarose gel electrophoresis. This test
incorporates reagents and enzymes for specific amplifi-
cation of a 260 bp region of N. gonorrhoeae’s PorA
gene. A second heterologous amplification system is
also used to identify possible PCR inhibition and/or
inadequate isolation.
Syphilis
Peripheral venipuncture was used to collect samples
which were used with an enzyme immunoassay (EIA)
method to detect IgM or IgG class antibodies (Abs)
directed against T. pallidum. This protocol involves
application of highly specific recombinant syphilis anti-
gens for Abs that arise early during the primary stage of
syphilis, and have lifelong positivity in most cases.
Hepatitis B & C, HIV
Microparticle enzyme immunoassay (MEIA) techniques
were used for qualitative detection of Hepatitis B surface
antigen (HBsAg) in human serum as well as detection of
antibodies to Hepatitis B core protein (anti-HBc). All
samples were run on an AxSYM Plus diagnostic platform
(Abbott Diagnostic Division Ltd., Abbott Park, Illinois
USA) utilizing microparticles coated with monoclonal
antibodies for the detection of the above markers. Sam-
ples non-reactive by this testing modality are considered
negative for Hepatitis B and need not be tested further.
MEIA was also used for qualitative detection of antibody
to hepatitis C virus (anti-HCV) in human serum. Simi-
larly, simultaneous qualitative detection of antibodies to
human immunodeficiency virus type 1 and/or type 2
(HIV-1/HIV-2) as well as the HIV p24 antigen in human
serum was also performed. This global HIV assay
(AxSYM HIV Ag/Ab Combo) does not, however, discri-
minate among HIV-1 antibody, HIV-2 antibody, or HIV
p24 antigen reactivity. For these tests, assay result was
determined by comparing fluorescent product formation
rate to a cut-off rate, derived from previous AxSYM
Index Calibrations. The sample is classified as reactive if
the rate of formation of fluorescent product in specimens
is greater than or equal to this threshold.
Analysis and follow-up protocol
In addition to results from the screening tests above,
female patient age and clinical pregnancy rate (per
embryo transfer) were recorded. Validation is required
for any positive screening result, with reflex testing per-
formed at the National Virus Reference Laboratory
(UCD-Ireland).
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Results
In the 24-month period ending January 2010, the mean
(±SD) age for 225 consecutive patients who enrolled in
anonymous donor oocyte IVF programme was 40.7 ±
4.2 yrs. At least one referring (primary care) physician
had provided negative test results for HIV, Hepatitis B/
C, chlamydia, gonorrhoea, and syphilis prior to repro-
ductive endocrinology consultation and IVF (average
interval between GP screening and re-screen = 31
months; range 2 - 60 months).
To comply with Directive 2004/23/EC as interpreted
by Statutory Instrument (SI) 158 of 2006, SI 598 of
2007, a 2007 IMB Draft, and other IMB communica-
tions, HIV, Hepatitis B/C, chlamydia, gonorrhoea, and
syphilis tests were again carried out at our centre and
designated “baseline studies”. All test results were
reviewed first by clinic personnel with secondary verifi-
cation by staff at the commercial laboratory responsible
for sample processing. All specimens were marked as
satisfactory for analysis and no positives were identified
for any specimen submitted. Among patients under-
going anonymous donor oocyte IVF, the mean clinical
pregnancy rate (per embryo transfer) during the study
interval was 50.5%. All patients completed IVF without
complications and there were no adverse events
reported among recipients or anonymous oocyte donors.
Discussion
In recent years, mean age of infertility patients at initial
consultation appears to have increased and has been
accompanied by a sharp rise in the number of prior
failed IVF cycles [7]. This refractoriness can be expected
to result in higher interest in anonymous oocyte dona-
tion IVF, although how best to screen these oocyte reci-
pients is not known with certainty. In Europe,
regulations detailing mandatory testing for any IVF
patients are lacking. The ESHRE Task Force on Ethics
and Law (2002) carefully studied the matter of gamete
and embryo donation, but did not recommend specific
testing requirements for recipients. The issue of oocyte
donation was addressed in more detail in the European
Union Tissues and Cells Directive (Directive 2004/23/
EC) [8], yet testing guidelines for recipients of donated
oocytes were again omitted. While this directive was
designed to assure medical consumers of the safest pos-
sible healthcare rendered at the best possible standards,
how exactly this objective should be applied to oocyte
recipients remains undefined. Europe’s key opinion lea-
ders in reproductive medicine have questioned the
appropriateness of applying this directive to general IVF
practice [9], and have highlighted the low yield (and
increased patient expense) associated with an unnecessa-
rily broad screening approach.
In Ireland, investigations focusing on screening data
from non-donor IVF patients have likewise concluded
that such individuals constitute a very low risk group,
where the level of disease surveillance in this subgroup
should be different compared to the general population.
For Irish IVF patients and the physicians who offer this
treatment here, the challenge to define proper testing is
particularly acute given the absence of any legislation
dealing with assisted reproductive techniques here [10].
The current report is the first to aggregate screening
data from recipients who underwent anonymous donor
oocyte IVF in Ireland; no positive screens were identi-
fied among 225 consecutive IVF cases completed during
the study interval. While our results are derived from a
particular sub-group of IVF patients (i.e., anonymous
donor oocyte recipients), these findings agree with gen-
eral pre-fertility treatment screening data independently
published from another leading Irish IVF centre [3]
where all test subjects also had negative screens. Taken
together, these factors make it increasingly difficult to
justify the current screening approach for IVF patients
in Ireland as mandated by Directive 2004/23/EC.
Making sure patients have no serious infection before
commencing fertility treatment is important. But since
patients in our study all had negative tests performed
with their GP or other primary care provider before
embarking on IVF treatment, our (repeat) screening
provided no additional clinically relevant information.
We can therefore endorse the general view that re-
screening of IVF patients in Ireland is not an effective
method to enhance patient safety [3]. Indeed, our study
permits refinement and extension of their conclusions
specifically to anonymous donor oocyte IVF recipients,
where repeat HIV, Hepatitis B/C, syphilis, gonorrhoea,
and chlamydia tests also yielded nothing but increased
patient cost and potential anxiety. We believe that if
such testing has already been carried out on the oocyte
recipient in a previous (primary care) setting with nega-
tive results, then this is sufficient a priori evidence that
“best practice standard” has been met. Continued use of
Directive 2004/23/EC to justify repeat testing for HIV,
Hepatitis B/C, syphilis, gonorrhoea, and chlamydia spe-
cifically among recipients of anonymous donor oocyte
IVF treatment is unwarranted in the absence of medical
evidence to quantify risks for this patient population.
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